INTRODUCTION {#S1}
============

Genomic efforts mainly through large-scale genome-wide association studies (GWAS), as part of the Alzheimer's Disease Genetics Consortium (ADGC)^[@R1]^ and the International Genomics of Alzheimer's Project (IGAP)^[@R2]^ have identified over 20 genes/loci for late-onset Alzheimer's disease (AD). However, known common AD variants account for only \~30% of the AD genetic variance^[@R3]^ and they also do not provide definitive information about underlying disease mechanisms. Genetic studies focusing on AD-related quantitative phenotypes/endophenotypes may help to identify additional AD-related genes. One such AD-related phenotype is deposition of amyloid-beta (Aβ) in the brain, which is one of the two main pathologic hallmarks of AD; the other being the formation of tau deposits in the form of neurofibrillary tangles, neuropil threads and dystrophic neurites (tau pathology) in the brain.^[@R4]^ According to the current model for sporadic AD, Aβ pathology occurs independently of tau pathology, is detectable earlier and is believed to accelerate neocortical tau pathology and neurodegeneration.^[@R5]^ Recent longitudinal studies on cognitively normal subjects also confirm that amyloidosis is an early process in AD.^[@R6],\ [@R7]^ The *in vivo* detection of Aβ deposition in the brain, as measured by positron emission tomography (PET) scanning with ^11^C-labeled Pittsburgh Compound-B (PiB) and the increased retention of PiB observed in the brains of AD patients compared to cognitively normal controls, was first reported by Klunk and colleagues^[@R8],\ [@R9]^ and since has been confirmed in many studies.^[@R10]^ There is a high correlation between amyloid PET imaging and neuritic plaque frequency as confirmed by autopsy studies.^[@R11]--[@R13]^ Multiple studies have shown that amyloid PET has a high value for the clinical diagnosis of AD and in clinical trials aiming to reduce brain Aβ burden.^[@R14]^

There is a well-established association of *APOE* variants with risk^[@R1],\ [@R2]^ and age-at-onset^[@R15],\ [@R16]^ of AD. Likewise, *APOE* genetic variation is also strongly associated with Aβ deposition in the brain as measured by PiB retention,^[@R17]--[@R19]^ indicating a genetic basis of Aβ deposition in the brain. Here, we used PiB-PET as an endophenotype to identify novel genetic loci for AD pathology using meta-analysis of three GWAS, the first to our knowledge, using the largest sample with the PiB-PET imaging from three different centers and the Alzheimer's Disease Neuroimaging Initiative (ADNI).

MATERIALS AND METHODS {#S2}
=====================

Sample description {#S3}
------------------

All subjects with PiB-PET data were European-Americans and derived from three sites: University of Pittsburgh (PITT), Washington University (WU) and Indiana University (IU) combined with the initial phase of the multicenter ADNI PiB-PET add-on study (here they are referred to as ADNI/IU). All subjects provided informed consent and all studies were approved by their local Institutional Review Boards. The summary statistics of these samples are included in [Supplementary Table S1](#SD1){ref-type="supplementary-material"} and their description is given [Supplementary Text](#SD1){ref-type="supplementary-material"}.

Amyloid-PET data {#S4}
----------------

Detailed methods for acquisition and processing of PiB-PET scans are described in previous reports for the PITT,^[@R17],\ [@R18]^ WU,^[@R19]^ ADNI^[@R20]--[@R22]^ and IU^[@R23]^ studies. PiB retention was measured in 4 cortical regions of the brain, including medial frontal cortex (MFC; anterior cingulate/gyrus rectus), lateral frontal cortex (LFC), precuneus cortex (PRC) and parietal cortex (PAR) and expressed as a ratio to the cerebellum. In the GWAS meta-analysis, the PiB retention values from these 4 cortical regions were averaged in each subject to calculate a mean global score (GBL4) as the quantitative endophenotype. PiB retention was expressed as standardized uptake volume ratio (SUVR) in the PITT and ADNI/IU data^[@R23],\ [@R24]^ and as binding potential (BP) in the WU data.^[@R25]^ BP is approximately equal to SUVR-1. Because of this inconsistency in the PiB measurement methods the GWAS data were analyzed via *P*-value based meta-analysis as described below.

Genotyping, imputation and quality control {#S5}
------------------------------------------

The genotyping platforms used for each study sample are listed in [Supplementary Table S1](#SD1){ref-type="supplementary-material"}. Imputation of non-genotyped single-nucleotide polymorphisms (SNPs) was performed with IMPUTE2^[@R26]^ using the 1000 Genomes Project^[@R27]^ Phase III (May 2013 release) data as the reference panel for PITT and Phase I (November 2010 release) data for WU and ADNI/IU datasets. Full description of these procedures is given in [Supplementary Text](#SD1){ref-type="supplementary-material"}.

Meta-analysis {#S6}
-------------

METAL^[@R28]^ software was used to perform meta-analysis on three GWAS using the mean PiB-PET GBL4 value. METAL performs a *P*-value based meta-analysis, which is appropriate when the effects being estimated are different in different cohorts. It does, however, account for differences in sample size between cohorts and for the direction of effects. The summary effect size was calculated by averaging the study-specific effect sizes, with weights reflecting the standard errors from the study-specific effect sizes.

Functional analyses {#S7}
-------------------

To evaluate the biological significance of PiB-associted signals, we conducted five different analyses: differential gene expression in AD versus non-AD in relevant tissues, brain gene expression, expression quantitative trait loci (eQTL) analyses, summary-data-based Mendelian randomization (SMR) analyses to test for pleiotropic association between gene expression and PiB, and pathway analyses. Detailed description of these analyses is given in [Supplementary Text](#SD1){ref-type="supplementary-material"}.

RESULTS {#S8}
=======

Amyloid PET data characteristics {#S9}
--------------------------------

The characteristics of participants in each of the three datasets included in the meta-analysis are shown in [Supplementary Table S1](#SD1){ref-type="supplementary-material"}. The WU sample was younger with less male participants. The distribution of mean global PiB retention is shown in [Figure 1](#F1){ref-type="fig"}.

GWAS Analysis {#S10}
-------------

Quantile-quantile (QQ) plots and lambda values for the meta-analysis showed that neither the results from each of the three component studies nor the combined results from meta-analysis were inflated in their test statistics ([Figure 2a](#F2){ref-type="fig"}). Meta-analysis revealed 27 genome-wide significant SNPs (*P*\<5E-08) in a four-gene region on chromosome 19: *PVRL2-TOMM40-APOE-APOC1*(**[Figure 2b](#F3){ref-type="fig"},** and [Supplementary Table S2](#SD2){ref-type="supplementary-material"}). As expected, *APOE\*4*/rs429358 showed the most significant association with the average global PiB retention (*P*-meta=9.09E-30; β=0.18; [Figure 3](#F4){ref-type="fig"}, [Supplementary Figure S1](#SD1){ref-type="supplementary-material"}).

Outside of the *APOE* region, no genome-wide significant signal was observed. However, the meta-analysis revealed 15 non-*APOE* loci with *P*\<1E-05 on chromosomes 8, 3, 15, 4, 21, 13, 2, 12 and 1 ([Table 1](#T1){ref-type="table"}). Most of these loci show quite consistent results across the all datasets. The regional plots of these 15 non-*APOE* loci are shown in [Supplementary Figures S2.1-S2.15](#SD1){ref-type="supplementary-material"}. The most significant SNP outside the *APOE* region is intergenic located between *ADCY8* - *EFR3A* on chromosome 8 (rs13260032; *P*=4.87E-07, [Supplementary Figure S2.1](#SD1){ref-type="supplementary-material"}). The next most significant SNP is also intergenic located between *RAP2B* - *C3orf79* on chromosome 3 (rs4680057; *P*=9.69E-07, [Supplementary Figure S2.2](#SD1){ref-type="supplementary-material"}). Chromosome 3 also harbors two additional signals: one in ncRNA (*LINC00971*/rs9831119; *P*=2.98E-06, [Supplementary Figure S2.6](#SD1){ref-type="supplementary-material"}) and another near *MAGEF1*/ rs11923588 (*P*=5.66E-06, Figure S2.9). The third most significant SNP is located in the *DAPK2* gene on chromosome 15 (rs12908891; *P*=1.39E-06, [Supplementary Figure S2.3](#SD1){ref-type="supplementary-material"}). We also analyzed the data after adjusting for the effect of *APOE\*4/*rs429358 in these non-*APOE* regions, which showed a slight attenuation of the association strengths ([Table 1](#T1){ref-type="table"}).

Conditional Analysis in the *APOE* Region {#S11}
-----------------------------------------

In order to check if there were independent SNPs associated with the PiB retention in the *APOE* region, we performed conditional analysis by adjusting for the top SNP (*APOE\*4*/rs429358). A total of 14 SNPs remained significant at *P*\<0.05 ([Table 2](#T2){ref-type="table"}), including 3 SNPs that showed genome-wide significance before adjusting for *APOE\*4* (rs75627662, rs483082 and rs438811; [Supplementary Table S2](#SD1){ref-type="supplementary-material"}). [Supplementary Figure S3](#SD1){ref-type="supplementary-material"} shows LD structure of these 14 SNPs along with *APOE\*4*/rs429358 and *APOE\*2*/rs7412 SNPs. *APOE\*4* and *APOE\*2* have essentially no LD with 9 of the 14 SNPs that are located in the *PVRL2* gene (SNPs 1--9 in [Supplementary Figure S3](#SD1){ref-type="supplementary-material"}). One SNP located in the *APOE*/*APOC1* intergenic region (rs59325138) has only very weak correlation with *APOE\*4* (R^2^=0.15) and *APOE\*2* (R^2^=0.03). While 3 SNPs located down stream of *APOE* and *APOE/APOC1* intergenic region have weak to moderate LD with *APOE\*4* (R^2^=0.42, 0.64, 0.65 for rs75627662, rs483082 and rs438811, respectively).

The most significant SNP in meta-conditional analysis was *APOE\*2*/rs7412 (*P*-meta=3.69E-03; β=−0.06; [Table 2](#T2){ref-type="table"}), though it was not genome-wide significant before adjusting for *APOE\*4* (*P*-meta=6.57E-05; β=−0.09). A similar strength of association was seen with an intronic *PVRL2*/rs3852859 SNP after adjusting for *APOE\*4* (*P*-meta=8.8E-03; β=0.06; [Table 2](#T2){ref-type="table"}) that was in LD with 3 additional SNPs (SNPs 1, 7, 9 in [Supplementary Figure S3](#SD1){ref-type="supplementary-material"}). Three additional apparently independent associations were seen with rs4803767 (*P*-meta=2.06E-02; β=0.05 [Table 2](#T2){ref-type="table"}) that was in LD with 4 additional SNPs (SNPs 2--5 in [Supplementary Figure S3](#SD1){ref-type="supplementary-material"}), rs75627662 (*P*-meta=1.50E-02; β=−0.03; [Table 2](#T2){ref-type="table"}) that was in LD with 2 additional SNPs (SNPs 13,15 in [Supplementary Figure S3](#SD1){ref-type="supplementary-material"}) and rs59325138 (*P*-meta=3.10E-02; β=0.03; [Table 2](#T2){ref-type="table"}) that has very weak correlation with all other SNPs (R^2^=0.01-- 0.24).

Association of known AD risk loci with amyloid burden and Association of amyloid loci with AD risk {#S12}
--------------------------------------------------------------------------------------------------

We examined the top IGAP genome-wide significant SNPs ([Supplementary Table S3.1](#SD1){ref-type="supplementary-material"}) and the associated gene regions ([Supplementary Table S3.2](#SD1){ref-type="supplementary-material"}) in relation to amyloid burden and found only some nominally significance SNPs. Likewise, we examined the suggestive non-*APOE* amyloid loci in our PITT-ADRC case-control sample of \>2,200 subjects^[@R29]^ and found association of two top amyloid-associated SNPs with AD risk ([Supplementary Table S4.1](#SD1){ref-type="supplementary-material"}). When we examined additional Aβ-associated SNPs in each region with AD risk, we found multiple associations with *P*\<0.05 ([Supplementary Table S4.2](#SD1){ref-type="supplementary-material"}), indicating that our suggestive Aβ-associated loci are also associated with AD risk (see [Supplementary Text](#SD1){ref-type="supplementary-material"} for more details).

Estimation of Amyloid-PET variance by *APOE* and non-*APOE* loci {#S13}
----------------------------------------------------------------

The genetic variance was estimated based on the R-square calculated from a linear regression model regressing global PiB retention on 6 independent *APOE* SNPs (rs429358, rs7412, rs3852859, rs4803767, rs75627662, rs59325138), as described above, and 15 non-*APOE* SNPs given in [Table 1](#T1){ref-type="table"}. The contribution of 6 *APOE* SNPs to the variance of global PiB retention was 28.0%, 17.3% and 17.12% in the PITT, WU and ADNI/IU datasets, respectively; *APOE\*4*/rs429358 alone explained 17.5%, 16.5% and 13.9%, respectively. The top 15 non-*APOE* SNPs explained 22.6%, 21.6% and 21.7% of the amyloid variance in the PITT, WU and ADNI/IU datasets, respectively. The consistency of these estimates across the different datasets gives confidence that the difference in measurement of PiB across the datasets does not affect the bottom-line results.

Functional analyses {#S14}
-------------------

We performed five analyses (see [Methods](#S2){ref-type="sec"} section) to evaluate the biological significance of PiB-implicated signals/genes. We considered all genes within ±500kb of the top variant in each locus from [Table 1](#T1){ref-type="table"} plus any eQTL-controlled genes outside the ±500kb boundary as target genes ([Figure 3](#F4){ref-type="fig"}, [Supplementary Figures S2.1-S2.15](#SD1){ref-type="supplementary-material"}), and selected a total of 257 genes.

Of 257 target genes, we found 20 upregulated and 25 downregulated genes that were differentially expressed in the same direction in two or more AD studies and no opposite directions were reported ([Table 3](#T3){ref-type="table"} and [Supplementary Table S6](#SD3){ref-type="supplementary-material"} marked in green color). Brain RNA-seq data reveals many of these differentially expressed candidate genes are expressed in AD-relevant cell types ([Table 3](#T3){ref-type="table"} and [Supplementary Table S6](#SD3){ref-type="supplementary-material"} marked in yellow color).

For eQTL analyses, we identified SNPs in LD (R^2^ ≥ 0.5) with the top SNP for each locus in [Table 1](#T1){ref-type="table"}. For these SNPs, there were *cis*-acting eQTLs (eQTL *P* \<0.05) for 151 of the 257 target genes in various brain tissues, and 36 genes in whole blood available in GTEx. [Supplementary Table S5](#SD1){ref-type="supplementary-material"} gives the eQTL results for each top SNP in 15 non-*APOE* loci and the detailed results of LD SNPs (R^2^≥0.80) with top SNPs are given in [Supplementary Table S7](#SD3){ref-type="supplementary-material"}**.** With the exception of *SLITRK1* /rs9831119, the other 14 top SNPs were eQTLs in different brain regions; 11 of them were eQTL in anterior cingulate cortex/frontal cortex/cortex where PiB intake is highest,^[@R30]^ indicating their role in affecting amyloid deposition in the brain.

For SMR analyses, only the gene/variant pairs identified in the *cis*-eQTL analyses were considered. For these gene/variant pairs, 99 genes in any brain tissue and 19 in whole blood were shown to mediate genetic effects on PiB by *cis*-regulating gene expression (SMR *P* \<0.05; [Table 3](#T3){ref-type="table"}, [Supplementary Table S6](#SD2){ref-type="supplementary-material"}).

We conducted pathway analyses (MAGMA^[@R31]^) using four gene set resources, including and excluding target genes in the *APOE* region, and detected nine genome-wide significant pathways: ndkdynamin pathway, *FDR*= 4.6E-04; synaptic vesicle recycling, *FDR*= 3.5E-07; synaptic vesicle endocytosis, *FDR*= 3.1E-04; protein depolymerization, *FDR*= 3.1E-04; inositol tetrakisphosphate phosphatase activity, *FDR*= 5.7E-03; positive regulation of vacuole organization, *FD* = 5.7E-03; inositol trisphosphate phosphatase activity, *FDR*= 0.033; regulation of clathrin-mediated endocytosis, *FDR*= 0.038; and clathrin-mediated endocytosis, *FDR* = 0.043. Although none of the 257 target genes, including *APOE*, are included in these nine genome-wide significant pathways, 71 target genes are included in the nominally significant pathways and 46 target genes are included in the non-*APOE* region-related nominally significant pathways (*P* \< 0.05. [Table 3](#T3){ref-type="table"} and [Supplementary Table S6](#SD2){ref-type="supplementary-material"} marked in pink color).

DISCUSSION {#S15}
==========

In this investigation, we have used the largest PiB-PET imaging data (n=\~1,000), available from multiple collaborative centers, as an endophenotype to identify novel genetic loci for AD pathology using the GWAS meta-analysis approach, the first to our knowledge for PiB-PET.

The *APOE* region showed the most significant association where several SNPs surpassed the genome-wide significant threshold *(P*\<5E-08) with *APOE\*4* as the top hit that was associated with higher PiB retention in the brain (*P*-meta=9.09E-30; β=0.18). *APOE\*2*, a protective genetic factor against AD, was associated with lower PiB retention, albeit, not genome-wide significant (*P*-meta=6.57E-05; β=−0.09). This observation is consistent with earlier reports of the association of the *APOE\* 2/3/4* polymorphism with Aβ deposition in the brain as measured by PiB-PET^[@R17]--[@R19]^ or florbetapir-PET.^[@R32]^ Likewise, a GWAS of cerebrospinal fluid (CSF) Aβ has identified a genome-wide significant SNP that was a proxy for *APOE\*4*.^[@R33]^ Numerous prior studies have investigated the role of the *APOE\* 2/3/4* polymorphism on Aβ production, aggregation and clearance in the brain,^[@R34]^ but recent studies provide solid mechanistic clues into the role of *APOE* genetic variation in affecting APP transcription and Aβ production,^[@R35]^ and seeding of amyloid pathology.^[@R36]^ In addition to the *APOE\*2/3/4* association, conditional analysis on *APOE\*4* identified 14 independent signals in the *APOE* region that also affect brain amyloidosis. Nine of 14 SNPs had essentially no LD with *APOE\*4* and *APOE\*2* and the remaining 5 showed moderate to weak LD with *APOE\*4*. Thus, our meta-analysis indicates the presence of additional signals in the *APOE* region, beyond the *APOE\*4*/rs429358 and *APOE\*2*/rs7412 SNPs, that affect Aβ deposition in the brain.

Outside the *APOE* region, the meta-analysis revealed 15 suggestive non-*APOE* loci with *P*\<1E-05 on nine chromosomes. Although they do not meet the established genome-wide significance criteria, their consistent and directional associations in three independent datasets ([Table 1](#T1){ref-type="table"}) suggest that at least some of them are likely candidate loci for brain amyloidosis process and/or AD risk and variants in these loci may have achieved the genome-wide significance threshold in larger datasets. Credence to this idea was provided by our observation that most of these suggestive loci were also associated with AD risk when we examined the Aβ-associated SNPs in a published AD GWAS^[@R29]^ ([Supplementary Tables S4.1-S4.2](#SD1){ref-type="supplementary-material"}). The most significant non-*APOE* SNP (rs13260032; *P*=4.87E-07) on chromosomes 8 is intergenic, and this was an eQTL for a nearby *ADCY8* gene in frontal cortex, which is one of the highest PiB uptake cortical regions.^[@R30]^ *ADCY8* is essential to long-term potentiation and synaptic plasticity and is implicated in memory and learning.^[@R37]^ Genetic variation in or around *ADCY8* has shown to be associated with dissociation symptoms in subjects with posttraumatic stress disorder,^[@R37]^ abdominal visceral^[@R38]^ and alcohol-dependent depression.^[@R39]^ The second top SNP (rs4680057; *P*=9.69E-07) resides near *C3orf79* and was an eQTL for a nearby long noncoding RNA (lncRNA) gene in anterior cingulate cortex and hippocampus in the brain and for *ARHGEF26* in blood. lncRNAs play a critical role in gene regulatory networks and may affect diverse biological processes and diseases,^[@R40]^ including AD where several IncRNAs have been shown to regulate Aβ production/generation.^[@R41],\ [@R42]^ A recent GWAS has identified *ARHGEF26* as a new genetic factor for coronary artery disease risk that influences the transendothelial migration of leukocytes.^[@R43]^ The third top SNP (rs12908891; *P*=1.39E-06) is located *DAPK2* on chromosome 15 that belongs to a family of related serine/threonine kinases shown to be involved in multiple functions, including apoptosis, autophagy, tumor suppression and inflammation.^[@R44]^ Although the role of *DAPK2* in amyloidosis in unknown, another family member, *DAPK1*, promotes the phosphorylation and amyloidogenic processing of APP.^[@R45]^ The *DAPK2* region contains other candidate genes, such as *GSNK1G1* and *TRIP4*. While *TRIP4* is a known gene for AD,^[@R46]^ *GSNK1G1* has been implicated in the formation of Aβ.^[@R47]^ The top SNP was the most significant eQTL for *HERC1* gene expression in anterior cingulate cortex (*P*=7.02E-05; *P*\_SMR=1.94E-03). HERC1 belongs to the ubiquitin--proteasome system that plays a key role in the protein degradation pathway essential for neuronal homeostasis, synaptic development and maintenance. Mutations in *HERC1* have been associated with intellectual disability^[@R48]^ and autism spectrum disorders.^[@R49]^

To identify additional PiB-relevant candidate genes, we combined results from the brain expression, differential brain expression in AD, eQTL/SMR in the brain, and pathway analyses. Four genes meeting all these functional criteria were identified: *RPS27L* in the *DAPK2* region, *CYP4V2* and *TLR3* in the *CYP4V2* region, and *IDH1* in the *IDH1/C2orf80* region ([Table 3](#T3){ref-type="table"}, [Supplementary Table S6](#SD3){ref-type="supplementary-material"}). RPS27L is an evolutionarily conserved ribosomal protein and a physiological regulator of transcription factor p53 that is involved in genomic stability and tumor suppression.^[@R50]^ p53 has also been implicated in AD progression, in part, due to its interaction with Aβ in AD progression.^[@R51]^ p53 also interact with IDH1 in glioblastoma.^[@R52]^ It seems that the involvement of RPS27L and IDH1 in the amyloidogenic process is through their effect on or interaction with p53. Although the role of CYP4V2 in amyloidosis is currently unclear, activated TLR3, along with some members of the toll-like receptors family, can induce Aβ uptake or inflammatory response during the AD progression.^[@R53]^ Further functional characterization of these candidate genes may help to elucidate their roles in brain amyloidosis.

A recent GWAS using CSFAβ42 as an endophenotype has identified two novel loci in addition to the *APOE* locus.^[@R33]^ One locus is near *GLIS1* on chromosome 1 and the other in *SERPINB1* on chromosome 6. The reported *GLIS1*/185031519 SNP was neither present in our genotyping array nor was it imputed. This SNP was also not in high LD with other SNPs. On the other hand, the reported *SERPINB1*/rs316341 SNP was present in our data, but it was not significant (*P*=0.148). We also examined four additional reported *SERPINB1* SNPs with *P*\<1E-05 (rs316339, rs316337, rs392120, rsrs2293772)^[@R33]^ and found one of them to be nominally significant in our data (rs392120; *P*=0.033).

We estimated the genetic variance of global PiB retention explained by the *APOE* and top 15 non-*APOE* SNPs with *P*\<1E-05 using a linear regression model. The non-*APOE* SNPs along with *APOE\*4* explained 25%−35% of the amyloid variance; of which 14--17% was explained by *APOE\*4* alone. A previous study using a different amyloid tracer (florbetapir-PET)^[@R32]^ found a similar contribution of *APOE\*4* (11%) to amyloid variance. However, a GWAS on CSF Aβ42 found a smaller contribution of *APOE\*4* (4%) to amyloid variance.^[@R33]^ This may be due to the use of different methods to estimate the amyloid variance. While the CSF study used the Genome-wide Complex Trait Analysis (GCTA) that requires \>3,000 sample size,^[@R54]^ the two amyloid tracer studies with smaller sample sizes used linear regression. Our data, in conjunction with previous studies, highlight the presence of yet to be discovered variants that may be responsible for the unexplained genetic variance of amyloid deposition.

As with any genome-wide study, this study has limitations. Although the present study used the largest combined sample of PiB-PET imaging data reported to-date (from three different centers and ADNI), the sample size was relatively small to achieve genome-wide significance for loci with small effect sizes. We predict that at least some of our suggestive loci with *P*\<1E-05 might have achieved genome-wide significance with a larger sample size, as the direction of allelic effects for all suggestive loci were consistent in all datasets. Unlike some other phenotypes where data could be obtained readily on large numbers of subjects at a relatively low-cost, this is not the case with amyloid PET. Thus, the lack of a very large PiB-PET imaging database for a genome-wide study was a significant constraint. As more PiB-PET imaging data are obtained by different centers, future collaborative studies, as done here, on larger samples may allow the identification of additional genes for brain amyloidosis.

In conclusion, this is the first GWAS on PiB-PET that has confirmed the established association of the *APOE* locus with *in vivo* brain amyloidosis. In addition to the known association, we have identified novel variants in the *APOE* region that affect amyloidosis. A combination of genetic and functional approaches has also led to the identification of additional putative candidate genes that warrant follow-up genetic and functional studies to confirm their role in brain amyloidosis.
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![Manhattan plot showing the *P*-values in the meta-analysis**.** The blue line represents the suggestive significance line (*P*\<E-05). The red line represents the significance threshold (*P*\<5E-08).](nihms-1502310-f0003){#F3}

![Regional plot of the *APOE* region on chromosome 19 in the meta-analysis. The relative location of genes and the direction of transcription are shown in the lower portion of the figure, and the chromosomal position is shown on the *x* -axis. The light blue line show the recombination rate across the region (right *y* -axis), and the left *y* axis shows the significance of the associations. The purple diamond shows the *P*-value for rs429358 that is the most significant SNP in the meta-analysis. The circles show the *P*-values for all other SNPs and are color coded according to the level of LD with rs429358 in the 1000 Genome Project EUR population.](nihms-1502310-f0004){#F4}

###### 

Genetic loci associated with PiB-PET with *P*\<1E-05 in the meta-analysis

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  SNP           Chr   Position    A1   A2   Gene                    Region           PITT   WU      ADNI/IU    Meta   Meta adjusted for\                                                                       
                                                                                                                      *APOE\*4*                                                                                
  ------------- ----- ----------- ---- ---- ----------------------- ---------------- ------ ------- ---------- ------ -------------------- ---------- ------ ------- ---------- ------- -------------- ------- ----------
  rs429358      19    45411941    C    T    *APOE*                  exonic           0.20   0.35    5.20E-12   0.21   0.16                 5.36E-16   0.28   0.19    7.88E-05   0.18    **9.09E-30**   NA      NA

  rs13260032    8     132451455   C    A    *ADCY8,EFR3A*           intergenic       0.43   -0.17   4.90E-05   0.44   -0.06                1.34E-02   0.43   -0.07   6.76E-02   -0.08   **4.87E-07**   -0.07   1.15E-05

  rs4680057     3     153096985   A    G    *RAP2B,C3orf79*         intergenic       0.45   0.16    2.60E-04   0.42   0.04                 1.93E-02   0.46   0.11    8.07E-03   0.06    **9.69E-07**   0.05    2.61E-05

  rs12908891    15    64236441    G    A    *DAPK2*                 intronic         0.46   0.12    6.38E-03   0.49   0.06                 5.77E-06   0.50   0.01    9.01E-01   0.06    **1.39E-06**   0.04    5.30E-04

  rs7377304     4     187129780   G    T    *CYP4V2*                intronic         0.42   0.08    8.84E-02   0.46   0.06                 5.98E-05   0.47   0.09    2.83E-02   0.06    **2.46E-06**   0.06    1.59E-05

  rs55708341    21    45627581    T    A    *C21orf33,ICOSLG*       intergenic       0.23   0.18    1.88E-04   0.18   0.05                 4.65E-03   0.19   0.07    2.26E-01   0.07    **2.51E-06**   0.06    6.74E-05

  rs9831119     3     84712077    C    T    *LINC00971*             ncRNA_intronic   0.12   -0.13   3.66E-02   0.14   -0.07                5.15E-04   0.12   -0.16   8.89E-03   -0.08   **2.98E-06**   -0.07   1.80E-05

  rs9531483     13    84244873    A    C    *SLITRK1*               intergenic       0.30   -0.12   7.81E-03   0.31   -0.06                5.62E-04   0.33   -0.07   1.12E-01   -0.06   **3.65E-06**   -0.05   8.45E-05

  rs6722000     2     209075957   G    A    *C2orf80,IDH1*          intergenic       0.21   0.14    7.27E-03   0.20   0.07                 3.92E-04   0.22   0.06    2.37E-01   0.07    **4.96E-06**   0.07    1.71E-05

  rs11923588    3     184459667   T    C    *MAGEF1,LOC101928992*   intergenic       0.07   -0.20   2.19E-02   0.06   -0.19                6.50E-05   0.06   -0.14   1.53E-01   -0.18   **5.66E-06**   -0.13   1.56E-03

  rs66837203    4     36897136    T    C    *DTHD1,MIR4801*         intergenic       0.06   0.24    9.85E-03   0.08   0.10                 3.53E-04   0.04   0.13    2.36E-01   0.11    **6.03E-06**   0.09    4.66E-04

  rs200028958   4     70923661    A    G    *HTN1*                  intronic         0.10   0.29    2.99E-05   0.11   0.09                 1.29E-03   0.09   -0.05   5.54E-01   0.10    **6.25E-06**   0.09    8.02E-05

  rs4526799     12    57280586    T    C    *HSD17B6,SDR9C7*        intergenic       0.34   -0.19   3.58E-05   0.34   -0.04                3.09E-02   0.36   -0.04   4.18E-01   -0.05   **7.26E-06**   -0.06   1.16E-06

  rs17105538    1     81315043    G    A    *ELTD1,LPHN2*           intergenic       0.13   0.13    3.65E-02   0.15   0.08                 2.08E-04   0.17   0.09    1.10E-01   0.08    **7.66E-06**   0.07    1.58E-05

  rs62121100    2     3093952     G    T    *LINC01250*             ncRNA_intronic   0.19   -0.20   1.09E-04   0.16   -0.05                1.03E-02   0.21   -0.04   4.79E-01   -0.07   **8.44E-06**   -0.06   2.90E-05

  rs1809136     2     11152180    G    C    *KCNF1,FLJ33534*        intergenic       0.07   0.28    5.91E-04   0.07   0.17                 5.45E-04   0.08   0.00    9.95E-01   0.16    **9.99E-06**   0.15    6.36E-05
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

A1: minor allele; A2: major allele.

###### 

Conditional analysis on SNPs reaching *P*\<0.05 in the *APOE* region with additional adjustment for *APOE\*4* (rs429358) in the meta-analysis

  SNP          Chr   Position   A1   A2   Gene           Region       PITT   WU      ADNI/IU    Meta   LD (R^2^) with                                                                       
  ------------ ----- ---------- ---- ---- -------------- ------------ ------ ------- ---------- ------ ---------------- ---------- ------ ------- ---------- ------- -------------- ------- ------
  rs7412       19    45412079   T    C    *APOE*         exonic       0.07   -0.21   7.63E-03   0.07   -0.04            1.45E-01   0.04   -0.06   5.49E-01   -0.06   **3.69E-03**   0.01    NA
  rs3852859    19    45379309   C    T    *PVRL2*        intronic     0.20   0.08    1.14E-01   0.20   0.05             1.10E-01   0.24   0.07    1.52E-01   0.06    **8.81E-03**   0.004   0.01
  rs2075642    19    45377467   A    G    *PVRL2*        intronic     0.20   0.07    1.78E-01   0.20   0.06             8.44E-02   0.22   0.07    1.33E-01   0.06    **1.11E-02**   0.004   0.01
  rs3852856    19    45361574   A    G    *PVRL2*        intronic     0.21   0.06    2.43E-01   0.20   0.07             3.16E-02   0.22   0.06    2.03E-01   0.06    **1.15E-02**   0.006   0.01
  rs75627662   19    45413576   T    C    *APOE*         downstream   0.23   -0.15   1.57E-02   0.23   -0.02            2.92E-01   0.26   -0.03   6.19E-01   -0.03   **1.50E-02**   0.42    0.21
  rs4803767    19    45372959   T    C    *PVRL2*        intronic     0.26   0.05    2.63E-01   0.28   0.04             1.56E-01   0.31   0.07    8.34E-02   0.05    **2.06E-02**   0.002   0.01
  rs60389450   19    45372184   C    A    *PVRL2*        intronic     0.26   0.04    3.20E-01   0.26   0.02             1.72E-01   0.31   0.07    8.34E-02   0.03    **2.72E-02**   0.003   0.01
  rs59325138   19    45416291   T    C    *APOE,APOC1*   intergenic   0.38   0.06    2.16E-01   0.36   0.02             2.50E-01   0.36   0.07    1.17E-01   0.03    **3.10E-02**   0.15    0.03
  rs483082     19    45416178   T    G    *APOE,APOC1*   intergenic   0.26   -0.10   1.60E-01   0.29   -0.04            1.59E-01   0.32   -0.06   4.51E-01   -0.05   **3.35E-02**   0.64    0.16
  rs8104483    19    45372354   G    T    *PVRL2*        intronic     0.27   0.03    4.65E-01   0.27   0.02             2.04E-01   0.32   0.09    4.20E-02   0.03    **3.67E-02**   0.003   0.01
  rs3729640    19    45381917   T    C    *PVRL2*        UTR3         0.20   0.08    9.33E-02   0.19   0.03             3.35E-01   0.23   0.04    4.33E-01   0.05    **3.79E-02**   0.004   0.01
  rs8104292    19    45372707   A    G    *PVRL2*        intronic     0.27   0.04    4.14E-01   0.28   0.03             2.62E-01   0.32   0.09    4.20E-02   0.04    **3.80E-02**   0.003   0.01
  rs438811     19    45416741   T    C    *APOE,APOC1*   intergenic   0.26   -0.10   1.60E-01   0.30   -0.04            1.84E-01   0.32   -0.06   4.51E-01   -0.04   **3.84E-02**   0.65    0.16
  rs58521715   19    45372129   T    A    *PVRL2*        intronic     0.27   0.03    4.65E-01   0.27   0.02             2.53E-01   0.32   0.09    4.20E-02   0.03    **4.50E-02**   0.004   0.01

A1: minor allele; A2: major allele.

###### The functional analysis results for target genes.

Out of 257 target genes, only genes meeting at least three functional criteria are listed. The criteria include: 1) differential expression in at least two Alzheimer disease studies, and up- or down-regulated consistently in different studies; 2) expression in brain cells (Barres website); 3) having *cis*-eQTL effects in any brain tissues using GTEx database (*P* \<0.05); 4) mediating genetic effects on PiB (SMR analysis with *P* \< 0.05) in any brain tissues; 5) having *cis*-eQTL effects in whole blood (*P* \<0.05); 6) mediating genetic effects on PiB (SMR analysis with *P* \< 0.05) in whole blood; and 7) included in nominally significant pathways. The detailed results are summarized in [Supplementary Table S6](#SD3){ref-type="supplementary-material"}.

  Locus              Target gene   Chr   Expression in brain (Barres)   Differential expression in AD   eQTL in blood   SMR in blood   eQTL in any brain tissues   SMR in any brain tissues   Pathway   Non-APOE locus pathway
  ------------------ ------------- ----- ------------------------------ ------------------------------- --------------- -------------- --------------------------- -------------------------- --------- ------------------------
  *APOE*             *APOC1*       19                                                                                                                                                                   
                     *APOC2*       19                                                                                                                                                                   
                     *APOE*        19                                                                                                                                                                   
                     *BCAM*        19                                                                                                                                                                   
                     *BCL3*        19                                                                                                                                                                   
                     *BLOC1S3*     19                                                                                                                                                                   
                     *CD3EAP*      19                                                                                                                                                                   
                     *CEACAM19*    19                                                                                                                                                                   
                     *CKM*         19                                                                                                                                                                   
                     *CLASRP*      19                                                                                                                                                                   
                     *CLPTM1*      19                                                                                                                                                                   
                     *ERCC1*       19                                                                                                                                                                   
                     *ERCC2*       19                                                                                                                                                                   
                     *EXOC3L2*     19                                                                                                                                                                   
                     *GEMIN7*      19                                                                                                                                                                   
                     *KLC3*        19                                                                                                                                                                   
                     *NKPD1*       19                                                                                                                                                                   
                     *PPP1R13L*    19                                                                                                                                                                   
                     *PVRL2*       19                                                                                                                                                                   
                     *TOMM40*      19                                                                                                                                                                   
                     *TRAPPC6A*    19                                                                                                                                                                   
                     *ZNF180*      19                                                                                                                                                                   
  *ADCY8, EFR3A*     *ADCY8*       8                                                                                                                                                                    
                     *EFR3A*       8                                                                                                                                                                    
  *RAP2B, C3orf79*   *RAP2B*       3                                                                                                                                                                    
                     *DHX36*       3                                                                                                                                                                    
  *DAPK2*            *CSNK1G1*     15                                                                                                                                                                   
                     *DAPK2*       15                                                                                                                                                                   
                     *FBXL22*      15                                                                                                                                                                   
                     *HERC1*       15                                                                                                                                                                   
                     *KIAA0101*    15                                                                                                                                                                   
                     *PPIB*        15                                                                                                                                                                   
                     *SNX1*        15                                                                                                                                                                   
                     *SNX22*       15                                                                                                                                                                   
                     *TRIP4*       15                                                                                                                                                                   
                     *USP3*        15                                                                                                                                                                   
                     *LACTB*       15                                                                                                                                                                   
                     *RPS27L*      15                                                                                                                                                                   
                     *RAB8B*       15                                                                                                                                                                   
                     *ZNF609*      15                                                                                                                                                                   
                     *PLEKHO2*     15                                                                                                                                                                   
                     *ANKDD1A*     15                                                                                                                                                                   
  *CYP4V2*           *CYP4V2*      4                                                                                                                                                                    
                     *FAM149A*     4                                                                                                                                                                    
                     *FAT1*        4                                                                                                                                                                    
                     *KLKB1*       4                                                                                                                                                                    
                     *MTNR1A*      4                                                                                                                                                                    
                     *SORBS2*      4                                                                                                                                                                    
                     *TLR3*        4                                                                                                                                                                    
  *C21orf33,*        *CSTB*        21                                                                                                                                                                   
  *ICOSLG*           *ICOSLG*      21                                                                                                                                                                   
                     *PFKL*        21                                                                                                                                                                   
                     *RRP1*        21                                                                                                                                                                   
                     *TRAPPC10*    21                                                                                                                                                                   
                     *HSF2BP*      21                                                                                                                                                                   
                     *RRP1B*       21                                                                                                                                                                   
                     *UBE2G2*      21                                                                                                                                                                   
  *LINC00971*        *CADM2*       3                                                                                                                                                                    
  *SLITRK1*          *SLITRK1*     13                                                                                                                                                                   
  *C2orf80, IDH1*    *C2orf80*     2                                                                                                                                                                    
                     *CRYGD*       2                                                                                                                                                                    
                     *FZD5*        2                                                                                                                                                                    
                     *IDH1*        2                                                                                                                                                                    
                     *PIKFYVE*     2                                                                                                                                                                    
                     *PLEKHM3*     2                                                                                                                                                                    
                     *PTH2R*       2                                                                                                                                                                    
  *MAGEF1,*          *CAMK2N2*     3                                                                                                                                                                    
  *LOC101928992*     *CHRD*        3                                                                                                                                                                    
                     *ECE2*        3                                                                                                                                                                    
                     *EHHADH*      3                                                                                                                                                                    
                     *EIF4G1*      3                                                                                                                                                                    
                     *EPHB3*       3                                                                                                                                                                    
                     *FAM131A*     3                                                                                                                                                                    
                     *VPS8*        3                                                                                                                                                                    
                     *PARL*        3                                                                                                                                                                    
                     *ABCC5*       3                                                                                                                                                                    
  *HTN1*             *ARAP2*       4                                                                                                                                                                    
                     *DTHD1*       4                                                                                                                                                                    
                     *SULT1B1*     4                                                                                                                                                                    
                     *UTP3*        4                                                                                                                                                                    
                     *DCK*         4                                                                                                                                                                    
                     *MOB1B*       4                                                                                                                                                                    
  *HSD17B6,*         *ATP5B*       12                                                                                                                                                                   
  *SDR9C7*           *BAZ2A*       12                                                                                                                                                                   
                     *GLS2*        12                                                                                                                                                                   
                     *HSD17B6*     12                                                                                                                                                                   
                     *MIP*         12                                                                                                                                                                   
                     *MYO1A*       12                                                                                                                                                                   
                     *NAB2*        12                                                                                                                                                                   
                     *NACA*        12                                                                                                                                                                   
                     *NDUFA4L2*    12                                                                                                                                                                   
                     *PRIM1*       12                                                                                                                                                                   
                     *PTGES3*      12                                                                                                                                                                   
                     *R3HDM2*      12                                                                                                                                                                   
                     *RDH16*       12                                                                                                                                                                   
                     *SDR9C7*      12                                                                                                                                                                   
                     *SHMT2*       12                                                                                                                                                                   
                     *SPRYD4*      12                                                                                                                                                                   
                     *STAT6*       12                                                                                                                                                                   
                     *TAC3*        12                                                                                                                                                                   
                     *TIMELESS*    12                                                                                                                                                                   
                     *TMEM194A*    12                                                                                                                                                                   
                     *ZBTB39*      12                                                                                                                                                                   
  *LPHN2*            *LPHN2*       1                                                                                                                                                                    
  *LINC01250*        *ADI1*        2                                                                                                                                                                    
                     *RNASEH1*     2                                                                                                                                                                    
                     *TRAPPC12*    2                                                                                                                                                                    
                     *TSSC1*       2                                                                                                                                                                    
  *KCNF1,*           *ATP6V1C2*    2                                                                                                                                                                    
  *FLJ33534*         *C2orf50*     2                                                                                                                                                                    
                     *E2F6*        2                                                                                                                                                                    
                     *KCNF1*       2                                                                                                                                                                    
                     *NOL10*       2                                                                                                                                                                    
                     *ROCK2*       2                                                                                                                                                                    
                     *GREB1*       2                                                                                                                                                                    
